Valencian Node of the Spanish Stem Cell Bank, Prince Felipe Research Centre (CIPF), Valencia, Spain.
In Vitro Cell Dev Biol Anim. 2010 Apr;46(3-4):317-26. doi: 10.1007/s11626-010-9285-3. Epub 2010 Feb 26.
Derivation of human embryonic stem cell lines has been a remarkable scientific achievement during the last decade. Human embryonic stem cells are regarded as an unlimited cell source for replacement therapy in regenerative medicine. Clearly, the scientific community requires proper derivation, characterization, and registration with the purpose of making them available for research and future medical applications worldwide. In this paper, we report our derivation work as the Valencian Node of the Spanish Stem Cell Bank in the generation, characterization, and registration of VAL-3, -4, -5, -6M, -7, -8, and 9 (www.isciii/htdocs/terapia/terapia_bancocelular.jsp). The derivation process was performed on microbiologically tested and irradiated human foreskin fibroblasts and designed to minimize contact with xeno-components in knockout Dulbecco's modified Eagle's medium supplemented with knockout serum replacement and basic fibroblast growth factor. Fingerprinting of the cell lines was performed to allow their identification and traceability. All lines were expressed at the mRNA and specific protein markers for undifferentiation and were found to be negative for classical differentiation markers such as neurofilament heavy chain (ectoderm), renin (mesoderm), and amylase (endoderm). All lines displayed high levels of telomerase activity and were shown to successfully overcome cryopreservation and thawing. Finally, we demonstrated the potential to differentiate in vitro (embryoid body formation) and in vivo (teratoma formation) into cell types from all three germ layers. Teratoma derived from all human embryonic stem cell lines present similar morphological features except VAL-8 that display more aggressive tumor behavior with a larger proportion of solid tissues, as opposed to cyst formation in the other cell lines.
人类胚胎干细胞系的衍生是过去十年中一项非凡的科学成就。人类胚胎干细胞被视为再生医学中替代疗法的无限细胞来源。显然,科学界需要进行适当的衍生、表征和注册,以便将其用于全球范围内的研究和未来的医学应用。在本文中,我们报告了我们作为西班牙干细胞库瓦伦西亚节点的衍生工作,生成、表征和注册了 VAL-3、-4、-5、-6M、-7、-8 和 9(www.isciii/htdocs/terapia/terapia_bancocelular.jsp)。衍生过程是在经过微生物测试和辐照的人包皮成纤维细胞上进行的,设计目的是尽量减少在 knock-out Dulbecco 改良 Eagle 培养基中添加 knock-out 血清替代物和碱性成纤维细胞生长因子时与异种成分的接触。对细胞系进行指纹识别,以允许其识别和可追溯性。所有系都表达未分化的 mRNA 和特异性蛋白标记物,并且对神经丝重链(外胚层)、肾素(中胚层)和淀粉酶(内胚层)等经典分化标记物呈阴性。所有系均显示高水平的端粒酶活性,并成功克服了冷冻保存和解冻。最后,我们证明了在体外(胚状体形成)和体内(畸胎瘤形成)分化为所有三个胚层的细胞类型的潜力。从所有人类胚胎干细胞系衍生的畸胎瘤具有相似的形态特征,但除了 VAL-8 之外,VAL-8 表现出更具侵略性的肿瘤行为,具有更大比例的实体组织,而其他细胞系则形成囊肿。